» Articles » PMID: 22552978

Merging of the National Cancer Institute-funded Cooperative Oncology Group Data with an Administrative Data Source to Develop a More Effective Platform for Clinical Trial Analysis and Comparative Effectiveness Research: a Report from the Children's...

Overview
Publisher Wiley
Date 2012 May 4
PMID 22552978
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The National Cancer Institute-funded cooperative oncology group trials have improved overall survival for children with cancer from 10% to 85% and have set standards of care for adults with malignancies. Despite these successes, cooperative oncology groups currently face substantial challenges. We are working to develop methods to improve the efficiency and effectiveness of these trials. Specifically, we merged data from the Children's Oncology Group (COG) and the Pediatric Health Information Systems (PHIS) to improve toxicity monitoring, to estimate treatment-associated resource utilization and costs, and to address important clinical epidemiology questions.

Methods: COG and PHIS data on patients enrolled on a phase III COG trial for de novo acute myeloid leukemia at 43 PHIS hospitals were merged using a probabilistic algorithm. Resource utilization summary statistics were then tabulated for the first chemotherapy course based on PHIS data.

Results: Of 416 patients enrolled on the phase III COG trial at PHIS centers, 392 (94%) were successfully matched. Of these, 378 (96%) had inpatient PHIS data available beginning at the date of study enrollment. For these, daily blood product usage and anti-infective exposures were tabulated and standardized costs were described.

Conclusions: These data demonstrate that patients enrolled in a cooperative group oncology trial can be successfully identified in an administrative data set and that supportive care resource utilization can be described. Further work is required to optimize the merging algorithm, map resource utilization metrics to the National Cancer Institute Common Toxicity Criteria for monitoring toxicity, to perform comparative effectiveness studies, and to estimate the costs associated with protocol therapy.

Citing Articles

Healthcare utilization disparities among children with high-risk neuroblastoma treated on Children's Oncology Group clinical trials.

Shoag J, Li Y, Getz K, Huang Y, Hall M, Naranjo A Pediatr Blood Cancer. 2024; 71(10):e31192.

PMID: 38997807 PMC: 11343658. DOI: 10.1002/pbc.31192.


Household income and health-related quality of life in children receiving treatment for acute myeloid leukemia: Potential impact of selection bias in health equity research.

Newman H, Li Y, Huang Y, Elgarten C, Myers R, Ruiz J Cancer Med. 2024; 13(7):e6966.

PMID: 38572962 PMC: 10993703. DOI: 10.1002/cam4.6966.


Supportive Care in Pediatric Oncology: Opportunities and Future Directions.

Freedman J, Beeler D, Bowers A, Bradford N, Cheung Y, Davies M Cancers (Basel). 2023; 15(23).

PMID: 38067252 PMC: 10705083. DOI: 10.3390/cancers15235549.


Association of the social disorganization index with time to first septic shock event in children with acute myeloid leukemia.

Ruiz J, Li Y, Cao L, Huang Y, Tam V, Griffis H Cancer. 2023; 130(6):962-972.

PMID: 37985388 PMC: 10922804. DOI: 10.1002/cncr.35109.


Medical Outcomes, Quality of Life, and Family Perceptions for Outpatient vs Inpatient Neutropenia Management After Chemotherapy for Pediatric Acute Myeloid Leukemia.

Getz K, Szymczak J, Li Y, Madding R, Huang Y, Aftandilian C JAMA Netw Open. 2021; 4(10):e2128385.

PMID: 34709389 PMC: 8554641. DOI: 10.1001/jamanetworkopen.2021.28385.


References
1.
Mahoney M, Sargent D, OConnell M, Goldberg R, Schaefer P, Buckner J . Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trials. J Clin Oncol. 2005; 23(36):9275-81. DOI: 10.1200/JCO.2004.00.0588. View

2.
Fisher B, Zaoutis T, Leckerman K, Localio R, Aplenc R . Risk factors for renal failure in pediatric patients with acute myeloid leukemia: a retrospective cohort study. Pediatr Blood Cancer. 2010; 55(4):655-61. PMC: 3909928. DOI: 10.1002/pbc.22601. View

3.
Scharf O, Colevas A . Adverse event reporting in publications compared with sponsor database for cancer clinical trials. J Clin Oncol. 2006; 24(24):3933-8. DOI: 10.1200/JCO.2005.05.3959. View

4.
Newman K, Ponsky T, Kittle K, Dyk L, Throop C, Gieseker K . Appendicitis 2000: variability in practice, outcomes, and resource utilization at thirty pediatric hospitals. J Pediatr Surg. 2003; 38(3):372-9; discussion 372-9. DOI: 10.1053/jpsu.2003.50111. View

5.
Sung L, Aplenc R, Zaoutis T, Groll A, Gibson B, Lehrnbecher T . Infections in pediatric acute myeloid leukemia: lessons learned and unresolved questions. Pediatr Blood Cancer. 2008; 51(4):458-60. DOI: 10.1002/pbc.21613. View